ABSTRACT
No disponible
Subject(s)
Male , Infant , Humans , Hemoglobinopathies/complications , Hemoglobinopathies/epidemiology , Splenectomy/methods , Sickle Cell Trait/epidemiology , Sickle Cell Trait/physiopathology , Sickle Cell Trait/prevention & control , Hemoglobin, Sickle/genetics , Hemoglobin SC Disease/diagnosis , Hemoglobin SC Disease/epidemiology , Hydroxyurea/therapeutic useSubject(s)
Disasters/prevention & control , International Cooperation , Pediatrics , Relief Work , HumansABSTRACT
No disponible
Subject(s)
Humans , Disasters/prevention & control , International Cooperation , Pediatrics , Relief WorkABSTRACT
Castleman disease or angiofollicular hyperplasia is a rare disorder included in the group of lymphoproliferative disorders. This entity was originally described by Castleman in 1956. The etiology remains unknown but it is postulated to be a reactive lymphoid hyperplasia due to chronic antigenic stimulation caused by a viral infection. The disease presents in young adults and is more frequent in women; it is exceptionally rare in the pediatric age group. It is classified into two clinical groups (localized disease and disseminated disease) and there are two histologic variants (hyaline-vascular and plasma cell Castleman disease). Localized disease is usually asymptomatic, has a good prognosis, and is the most common presentation in pediatric patients, usually corresponding to highly vascularized mediastinal masses. Resection of the mass, which is curative, is associated with a high risk of blood loss. Recently, preoperative arteriography with embolization has been used satisfactorily in the preoperative management of these tumors. We present a case of localized Castleman disease in a 12-year-old girl satisfactorily treated with embolization before curative resection.
Subject(s)
Castleman Disease/therapy , Castleman Disease/diagnosis , Child , Embolization, Therapeutic , Female , Humans , MediastinumABSTRACT
La enfermedad de Castleman o hiperplasia angiofolicular es una entidad poco frecuente enmarcada dentro de los trastornos linfoproliferativos. Esta enfermedad fue descrita inicialmente por Castleman en 1956. Su etiología es desconocida, pero se cree que responde a una estimulación antigénica crónica de probable etiología viral. Se presenta en adultos jóvenes, más frecuente en mujeres, y es excepcional en la edad pediátrica. Clínicamente se distinguen dos formas de enfermedad: una localizada y otra multicéntrica. La forma localizada, de buen pronóstico, asintomática al diagnóstico, es la forma de presentación más frecuente en la edad pediátrica y por lo general corresponde a masas mediastínicas muy vascularizadas. La resección de la lesión, que es curativa, se asocia a un alto riesgo de sangrado. Recientemente se ha introducido la arteriografía con embolización prequirúrgica para minimizar el riesgo de sangrado en el acto quirúrgico. Se presenta un caso de enfermedad de Castleman localizada en una paciente de 12 años en la que se utilizó con éxito la angioembolización prequirúrgica
Castleman disease or angiofollicular hyperplasia is a rare disorder included in the group of lymphoproliferative disorders. This entity was originally described by Castleman in 1956. The etiology remains unknown but it is postulated to be a reactive lymphoid hyperplasia due to chronic antigenic stimulation caused by a viral infection. The disease presents in young adults and is more frequent in women; it is exceptionally rare in the pediatric age group. It is classified into two clinical groups (localized disease and disseminated disease) and there are two histologic variants (hyaline-vascular and plasma cell Castleman disease). Localized disease is usually asymptomatic, has a good prognosis, and is the most common presentation in pediatric patients, usually corresponding to highly vascularized mediastinal masses. Resection of the mass, which is curative, is associated with a high risk of blood loss. Recently, preoperative arteriography with embolization has been used satisfactorily in the preoperative management of these tumors. We present a case of localized Castleman disease in a 12-year-old girl satisfactorily treated with embolization before curative resection
Subject(s)
Female , Child , Humans , Castleman Disease/therapy , Embolization, Therapeutic , Castleman Disease/diagnosis , MediastinumABSTRACT
We present the case of a 6-year old boy with a mid-muscular residual ventricular septal defect (VSD) of difficult surgical access, who underwent transcatheter closure using the Amplatzer(TM) VSD occluder. Transcatheter closure was guided by transthoracic echocardiography and successful closure was achieved with a 12 mm diameter VSD occluder, with no complications. Chest radiography showed a considerable decrease in cardiomegaly and normalization of pulmonary vascular markings before 24 hours, and echocardiography showed correct positioning of the Amplatzer(TM) VSD device without residual shunt through the device and minimal residual shunt in an apical VSD. After a 3-month follow-up, the patient was asymptomatic and echocardiography showed that the device was correctly positioned with minimal residual apical shunt.
Subject(s)
Cardiac Catheterization/instrumentation , Heart Septal Defects, Ventricular/surgery , Child , Equipment Design , Heart Septal Defects, Ventricular/diagnostic imaging , Humans , Male , RadiographyABSTRACT
Se presenta el caso de un niño de 6 años de edad, afectado de una comunicación interventricular (CIV) muscular residual medioventricular de difícil acceso quirúrgico, en la que se procedió al cierre mediante cateterismo con el dispositivo Amplatzer Muscular VSD Occluder. El procedimiento se realizó guiado por ecocardiografía transtorácica consiguiendo la implantación del dispositivo de 12 mm de tamaño sin incidencias ni complicaciones. A las 24 h el paciente fue dado de alta previa realización de una radiografía de tórax que muestra una disminución importante tanto de la cardiomegalia como de la circulación pulmonar y una ecocardiografía que evidencia el dispositivo correctamente situado en el tabique interventricular sin flujo a su través, y con una CIV residual mínima. Tras un seguimiento de 3 meses el paciente esta asintomático y la ecocardiografía muestra el dispositivo correctamente situado con mínima CIV residual apical (AU)
